Shanghai Fosun Pharmaceutical Group Co. Ltd. has agreed to buy an 86 percent stake in Gland Pharma – backed by KKR & Co. LP – for up to $1.3 billion, the largest acquisition of an Indian company from abroad in 2016.
Boston Scientific Corp. reported better-than-expected quarterly sales as it sold more of its heart devices and revenue from its troubled cardiac rhythm management business increased.
Beginning in 2017, drugmaker Eli Lilly will have an increased focus on dealmaking under the leadership of its incoming chief executive officer David Ricks, Reuters reported.
Along with its dismal half-year financial reports, UK-based AstraZeneca announced it was halting six pipeline programs.
A study of one million people has found that physical inactivity costs the global economy $67.5 billion a year in healthcare and productivity losses, but an hour a day of exercise could eliminate most of that.
The Ice Bucket Challenge that went viral two years ago – raising hundreds of millions of dollars – has helped identify a new gene behind the neurodegenerative disease ALS, or Lou Gehrig’s disease, researchers say.
TauRx Pharmaceuticals’ experimental Alzheimer’s drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer’s disease.
Health insurer Anthem Inc. said it was committed to its planned acquisition of Cigna Corp. and again vowed to fight U.S. government efforts to block the deal, saying the merger will help lower costs for consumers.
International Business Machines Corp. said it would provide its technology and resources to help track the spread of the Zika virus.
GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.